欧林生物（688319）：破伤风疫苗龙头，金葡菌疫苗全球创新

Investment Rating - The report initiates coverage with a "Buy" rating for the company [11]. Core Insights - The company is a leader in the tetanus vaccine market, providing stable cash flow, while the staphylococcus aureus vaccine is emerging as a new growth driver. The company is continuously leading the industry during market expansion [3]. - The company has a robust pipeline with a focus on innovative vaccines for superbugs, including the recombinant staphylococcus aureus vaccine and others targeting Helicobacter pylori, Acinetobacter baumannii, and Pseudomonas aeruginosa [6][48]. Summary by Relevant Sections Company Overview - The company specializes in the research, production, and sales of human vaccines, having launched its first product, the adsorbed tetanus vaccine, in 2016. It has since expanded its product line to include vaccines for Hib and meningococcal diseases [19][30]. Financial Performance - The company expects revenues of CNY 704 million, CNY 727 million, and CNY 760 million for 2025-2027, with net profits of CNY 22.23 million, CNY 37.64 million, and CNY 44.05 million respectively. The earnings per share (EPS) are projected to be CNY 0.05, CNY 0.09, and CNY 0.11 for the same period [9]. Product Pipeline - The company has three products currently on the market: adsorbed tetanus vaccine, Hib vaccine, and meningococcal polysaccharide conjugate vaccine. It is also advancing four global class 1.1 new drug projects, including the recombinant staphylococcus aureus vaccine, which is in phase III clinical trials [6][48]. Market Position - The company holds a dominant position in the tetanus vaccine market, with a favorable competitive landscape and minimal pressure from new entrants. The tetanus vaccine primarily targets populations at risk of injuries and blood product clients, with a rigid sales channel [7][29]. Research and Development - The company has a strong R&D team, with 128 personnel dedicated to vaccine development, representing 27.65% of its workforce. It has established multiple research platforms and maintains collaborations with domestic and international research institutions [42][43].